CLINICAL TRIAL

Magnetic Resonance Imaging for Prostate Cancer

Waitlist Available · 18+ · Male · Houston, TX

This study is evaluating whether a modified MRI scan technique can help detect prostate cancer.

See full description

About the trial for Prostate Cancer

Eligible Conditions
Prostatic Neoplasms · Prostate Cancer

Treatment Groups

This trial involves 2 different treatments. Magnetic Resonance Imaging is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Dixon MRI
PROCEDURE
Magnetic Resonance Imaging
PROCEDURE
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Magnetic Resonance Imaging
2017
Completed Phase 2
~1120

Eligibility

This trial is for male patients aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:View All
Odds of Eligibility
High>50%
You meet most of the criteria! It's probably a good idea to apply to 1 other trial just in case this doesn't work out.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: through study completion, an average of 1 year
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: through study completion, an average of 1 year.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Magnetic Resonance Imaging will improve 1 primary outcome in patients with Prostate Cancer. Measurement will happen over the course of through study completion, an average of 1 year.

Detection of at least one or more prostate lesions with Dixon sequencing
THROUGH STUDY COMPLETION, AN AVERAGE OF 1 YEAR
Will evaluate and compare the accuracy of Dixon based sequencing to the conventional T2 weighted sequencing for detection of intraprostatic tumor and extraprostatic tumor extension. Lesions will be within any of six regions of the prostate: left apex, left mid, left base, right apex, right mid, and right base. The relative sensitivity and specificity of the two sequencing methods will be compared using an adjusted McNemar's test for clustered data where clusters consist of the matched pairs of within patient-zone observations. The primary analysis will also provide 95% confidence intervals for marginal sensitivity and specificity using a generalized linear mixed model.

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of prostate cancer?

Prostate cancer often presents with no symptoms at all. Symptoms usually appear after the cancer has started to spread to nearby pelvic lymph nodes. Most prostate cancers do not cause any pain during urination. Signs and symptoms can vary depending on the stage of the disease and how far it has spread. The primary signs include increased difficulty passing urine, backache, unexplained bleeding, a lump in the pelvis, painful sex, loss of sexual desire, a change in the shape of the penis or body, or problems with bladder control. Other less common ways that prostate cancer can present are urinary frequency, feeling incomplete emptying of the bladder, swollen lymph nodes around the groin area, loss of appetite, and bone pains.

Anonymous Patient Answer

How serious can prostate cancer be?

Prostate cancer is relatively uncommon among men under 50 years old. However, it kills more men than breast cancer or colon cancer combined. The survival rate after treatment is 10 percent less than that of women with breast cancer, but only 2 percent worse than that of men with colon cancer. It is therefore important to diagnose and treat prostate cancer as soon as possible.

Anonymous Patient Answer

What are the chances of developing prostate cancer?

Men whose relatives were diagnosed with prostate cancer have approximately 50% increased odds of having prostate cancer themselves. This effect appears to operate through both genetic linkage and shared environmental effects. The percentage of men who develop prostate cancer does not appear to differ significantly among men who are more than five years younger at diagnosis of prostate cancer than it does among men ages 40 to 65 years older.

Anonymous Patient Answer

What is magnetic resonance imaging?

MRI has provided all the information needed for definitive diagnosis of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer). Improvements are awaited in terms of detection of tumour extent in the peripheral regions of the prostate.

Anonymous Patient Answer

Have there been other clinical trials involving magnetic resonance imaging?

MRI offers several advantages over CT scans and ultrasound when looking at the prostate. It can provide more information on the status of the prostate than other imaging techniques can. MRI also has fewer artifacts than CT images. Therefore, MRI is a superior method for pelvic imaging.

Anonymous Patient Answer

What is the primary cause of prostate cancer?

The causes of prostate cancer are multifactorial, including genetic, environmental, behavioural and hormonal factors. The most likely combination of these factors are thought to be responsible for the development of prostate cancer. The causative roles of cigarette smoking and alcohol consumption remain unclear.

Anonymous Patient Answer

How quickly does prostate cancer spread?

The findings suggest that metastases occur within 12 weeks after diagnosis of invasive PCa. However, distant metastases are relatively rare in patients with early stage disease, and their occurrence is associated with shorter survival. Early detection of metastases should therefore be encouraged.

Anonymous Patient Answer

What is the average age someone gets prostate cancer?

Overall, the average age at diagnosis was 68 years old for all [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer)s. But for localized cancers, it was 51 years older (P<0.001). Median age at diagnosis was 66 years for advanced prostate cancer. And mean age at diagnosis was 65 years for localized disease (P<0.001), 67 years for locally recurrent/metastatic (P<0.001) prostate cancer, and 79 years for metastatic prostate cancer (P<0.001).

Anonymous Patient Answer

What does magnetic resonance imaging usually treat?

MR is frequently used as a diagnostic tool for determining the extent of pelvic and para-aortic lymphadenopathy in patients presenting with advanced prostate cancer. The addition of MRI to traditional staging techniques resulted in no change in treatment decisions in more than half of our patients. The value of MRI in the evaluation of patients with organ-confined disease remains unclear and warrants further investigation.

Anonymous Patient Answer

Is magnetic resonance imaging typically used in combination with any other treatments?

MRI was often used as part of treatment planning but was not typically combined with other forms of therapy. Further study into the use of MRI during treatment is warranted.

Anonymous Patient Answer

Does prostate cancer run in families?

Recent findings do not support the existence of any familial pattern of prostate cancer among our study population. It is important to note that this information does not exclude the possibility that the genetic basis for prostate cancer might exist but has yet to be discovered.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Prostate Cancer by sharing your contact details with the study coordinator.